TRAJENTA® has demonstrated significant and sustained HbA1c reductions.
TRAJENTA® efficacy at the dose of 5 mg once daily has been proven in a broad range of patients with type 2 diabetes. After 6 months of treatment, patients with T2D treated with TRAJENTA® experienced significant HbA1c reductions.1
Adjusted mean HbA1c change from baseline at 24 weeks in high baseline patients*1
In addition to being an effective monotherapy, TRAJENTA® also has demonstrated efficacy in reducing HbA1c in dual or triple combination with metformin, sulphonylurea, pioglitazone and basal insulin.2 Please refer to the Summary of Product Characteristics for more information about approved combinations.
*Pooled analysis of data from 2,258 subjects in three 24-week phase III, randomised, placebo-controlled, parallel-group studies, who received oral TRAJENTA® (5 mg/day) or placebo as monotherapy, added-on to metformin, or added-on to metformin plus sulphonylurea was performed. TRAJENTA® adjusted mean HbA1c change from baseline -1.2% (vs. -0.4%, placebo), p<0.0001.